Letetresgene autoleucel
- Generic Name
- Letetresgene autoleucel
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- B5ME4ZU4BS
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 7
- Registration Number
- NCT05993299
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03168438
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath